LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIAL
Eleonora Calabretta(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Matthew Sugidono(University of California, San Francisco), P. Armand(Dana-Farber Cancer Institute), Yanwen Jiang, Oscar Cazares, Kun Ping Lu(University of North Carolina at Chapel Hill), Alex F. Herrera(City of Hope), Gaddy Getz(Broad Institute), F. Jardin(Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers), Georg Lenz(Charité - Universitätsmedizin Berlin), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Franck Morschhauser(Hôpital Claude Huriez), Jennifer L. Crombie(Dana-Farber Cancer Institute), Motohiro Murakami(Dana-Farber Cancer Institute), Xia Zhao(Sichuan University), Chip Stewart(Broad Institute), Maria C. Palazzo(Dana-Farber Cancer Institute), W. Harris
Cited by 9
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
|Signal Transduction and Targeted Therapy|2020|1.7k